United States Biotechnology & Medical Research

Principia Biopharma Inc (PRNB)

Track

Track

Ticker: PRNB Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Hardiman Roy C. Chief Business Officer Officer
Transaction date
Planned sale
Price
307.03
Quantity 70,440 +9.8%
Value US$1,683,530
CHAI CHRISTOPHER Y Chief Financial Officer Officer
Transaction date
Planned sale
Price
11.76
Quantity 52,104 -10.1%
Value US$1,063,725
Thomas Dolca Chief Medical Officer Officer
Transaction date
Planned sale
Price
220.60
Quantity 57,155 -16.2%
Value US$4,864,688
Goldstein David M Chief Scientific Officer Officer
Transaction date
Planned sale
Price
93.34
Quantity 100 -0.3%
Value US$9,334
Goldstein David M Chief Scientific Officer Officer
Transaction date
Planned sale
Price
90.99
Quantity 1,108 -3.4%
Value US$100,816
Goldstein David M Chief Scientific Officer Officer
Transaction date
Planned sale
Price
89.68
Quantity 700 -2.1%
Value US$62,773
Goldstein David M Chief Scientific Officer Officer
Transaction date
Planned sale
Price
88.40
Quantity 2,534 -7.0%
Value US$224,012
Goldstein David M Chief Scientific Officer Officer
Transaction date
Planned sale
Price
86.92
Quantity 700 -1.9%
Value US$60,844
Goldstein David M Chief Scientific Officer Officer
Transaction date
Planned sale
Price
86.11
Quantity 858 -2.3%
Value US$73,886
Thomas Dolca Chief Medical Officer Officer
Transaction date
Planned sale
Price
80.07
Quantity 15,000 -89.1%
Value US$1,201,070
0.8
Colowick Alan Non-Executive Director
Transaction date
Planned sale
Price
60.00
Quantity 7,500 -100.0%
Value US$450,000
0.5
Babler Martin President, CEO Executive Director
Transaction date
Planned sale
Price
62.38
Quantity 2,502 -75.5%
Value US$156,078
0.5
Babler Martin President, CEO Executive Director
Transaction date
Planned sale
Price
61.82
Quantity 11,983 -78.3%
Value US$740,745
0.5
Babler Martin President, CEO Executive Director
Transaction date
Planned sale
Price
60.32
Quantity 515 -3.3%
Value US$31,066
3.5
Wolff Stefani Chief Development Officer Officer
Transaction date
Planned sale
Price
61.37
Quantity 100 -0.5%
Value US$6,137
3.5
Wolff Stefani Chief Development Officer Officer
Transaction date
Planned sale
Price
60.81
Quantity 5,004 -20.7%
Value US$304,291
3.5
Wolff Stefani Chief Development Officer Officer
Transaction date
Planned sale
Price
59.89
Quantity 400 -1.6%
Value US$23,957
Hardiman Roy C. Chief Business Officer Officer
Transaction date
Planned sale
Price
62.13
Quantity 863 -0.7%
Value US$53,617
Hardiman Roy C. Chief Business Officer Officer
Transaction date
Planned sale
Price
61.62
Quantity 2,542 -2.1%
Value US$156,630
Hardiman Roy C. Chief Business Officer Officer
Transaction date
Planned sale
Price
59.90
Quantity 1,595 -1.3%
Value US$95,541
CHAI CHRISTOPHER Y Chief Financial Officer Officer
Transaction date
Planned sale
Price
65.10
Quantity 7,500 -67.9%
Value US$488,268
Goldstein David M Chief Scientific Officer Officer
Transaction date
Planned sale
Price
60.39
Quantity 2,719 -8.1%
Value US$164,207
Goldstein David M Chief Scientific Officer Officer
Transaction date
Planned sale
Price
59.96
Quantity 3,281 -8.9%
Value US$196,734
0.8
Colowick Alan Non-Executive Director
Transaction date
Planned sale
Price
60.00
Quantity 6,660 -100.0%
Value US$399,600
0.8
Colowick Alan Non-Executive Director
Transaction date
Planned sale
Price
60.07
Quantity 840 -100.0%
Value US$50,457
3.5
Wolff Stefani Chief Development Officer Officer
Transaction date
Planned sale
Price
46.36
Quantity 3,750 -9.5%
Value US$173,838
3.5
Wolff Stefani Chief Development Officer Officer
Transaction date
Planned sale
Price
45.72
Quantity 1,754 -4.3%
Value US$80,192
Hardiman Roy C. Chief Business Officer Officer
Transaction date
Planned sale
Price
51.04
Quantity 100 -0.1%
Value US$5,104
Hardiman Roy C. Chief Business Officer Officer
Transaction date
Planned sale
Price
49.46
Quantity 1,181 -1.0%
Value US$58,408
Hardiman Roy C. Chief Business Officer Officer
Transaction date
Planned sale
Price
48.21
Quantity 3,719 -3.1%
Value US$179,304
0.5
Babler Martin President, CEO Executive Director
Transaction date
Planned sale
Price
64.83
Quantity 300 -0.8%
Value US$19,448
0.5
Babler Martin President, CEO Executive Director
Transaction date
Planned sale
Price
64.10
Quantity 5,432 -12.1%
Value US$348,180
0.5
Babler Martin President, CEO Executive Director
Transaction date
Planned sale
Price
63.24
Quantity 7,183 -13.8%
Value US$454,251
0.5
Babler Martin President, CEO Executive Director
Transaction date
Planned sale
Price
62.45
Quantity 2,085 -3.8%
Value US$130,203
CHAI CHRISTOPHER Y Chief Financial Officer Officer
Transaction date
Planned sale
Price
68.52
Quantity 76 -1.6%
Value US$5,208
CHAI CHRISTOPHER Y Chief Financial Officer Officer
Transaction date
Planned sale
Price
68.13
Quantity 2,240 -31.6%
Value US$152,612
CHAI CHRISTOPHER Y Chief Financial Officer Officer
Transaction date
Planned sale
Price
67.08
Quantity 605 -7.9%
Value US$40,582
CHAI CHRISTOPHER Y Chief Financial Officer Officer
Transaction date
Planned sale
Price
65.94
Quantity 1,350 -14.9%
Value US$89,021
CHAI CHRISTOPHER Y Chief Financial Officer Officer
Transaction date
Planned sale
Price
64.91
Quantity 545 -5.7%
Value US$35,375
CHAI CHRISTOPHER Y Chief Financial Officer Officer
Transaction date
Planned sale
Price
63.86
Quantity 2,684 -21.9%
Value US$171,389
Goldstein David Chief Scientific Officer Officer
Transaction date
Planned sale
Price
71.11
Quantity 5,200 -14.4%
Value US$369,779
Goldstein David Chief Scientific Officer Officer
Transaction date
Planned sale
Price
69.53
Quantity 800 -2.2%
Value US$55,622
Thomas Dolca Chief Medical Officer Officer
Transaction date
Sale
Price
60.00
Quantity 495 -50.1%
Value US$29,700
Babler Martin President, CEO Executive Director
Transaction date
Planned sale
Price
54.28
Quantity 1,295 -7.6%
Value US$70,292
Babler Martin President, CEO Executive Director
Transaction date
Planned sale
Price
53.69
Quantity 2,205 -11.5%
Value US$118,392
Babler Martin President, CEO Executive Director
Transaction date
Planned sale
Price
52.77
Quantity 1,000 -5.0%
Value US$52,775
Babler Martin President, CEO Executive Director
Transaction date
Planned sale
Price
54.36
Quantity 1,014 -1.8%
Value US$55,116
Babler Martin President, CEO Executive Director
Transaction date
Planned sale
Price
53.94
Quantity 6,661 -10.8%
Value US$359,314
Babler Martin President, CEO Executive Director
Transaction date
Planned sale
Price
52.86
Quantity 11,485 -15.7%
Value US$607,064
Babler Martin President, CEO Executive Director
Transaction date
Planned sale
Price
51.80
Quantity 5,840 -7.4%
Value US$302,502
Wolff Stefani Chief Development Officer Officer
Transaction date
Planned sale
Price
49.87
Quantity 1,300 -3.5%
Value US$64,825
Wolff Stefani Chief Development Officer Officer
Transaction date
Planned sale
Price
49.29
Quantity 4,205 -10.2%
Value US$207,266
Hardiman Roy C. Chief Business Officer Officer
Transaction date
Planned sale
Price
49.83
Quantity 1,619 -1.3%
Value US$80,682
Hardiman Roy C. Chief Business Officer Officer
Transaction date
Planned sale
Price
49.20
Quantity 3,381 -2.7%
Value US$166,352
Becker Daniel J. Non-Executive Director
Transaction date
Purchase
Price
29.94
Quantity 55,000 +9.0%
Value US$1,646,700
Goldstein David Chief Scientific Officer Officer
Transaction date
Planned sale
Price
32.39
Quantity 10,000 -25.1%
Value US$323,914
3.2
Becker Daniel J.
Transaction date
Purchase
Price
33.98
Quantity 9,196 +1.5%
Value US$312,477
3.2
Becker Daniel J.
Transaction date
Purchase
Price
33.41
Quantity 68,404 +12.8%
Value US$2,285,549
2.3
GLAXOSMITHKLINE PLC
Transaction date
Purchase
Price
28.00
Quantity 357,142 +13.6%
Value US$9,999,976
3.2
Becker Daniel J.
Transaction date
Purchase
Price
28.00
Quantity 535,000 +inf%
Value US$14,980,000
3.1
George Simeon
Transaction date
Purchase
Price
28.00
Quantity 357,142 +13.6%
Value US$9,999,976
New Leaf Ventures II, L.P. Large shareholder
Transaction date
Sale
Price
35.00
Quantity 49,991 -11.4%
Value US$1,749,685
New Leaf Ventures II, L.P. Large shareholder
Transaction date
Sale
Price
35.00
Quantity 250,009 -11.4%
Value US$8,750,315
2.6
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Sale
Price
30.25
Quantity 1,000,000 -38.4%
Value US$30,250,000
GLAXOSMITHKLINE PLC Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 270,000 +11.5%
Value US$4,590,000
Becker Daniel J. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 270,000 +161.2%
Value US$4,590,000
AKKARAJU SRINIVAS Non-Executive Director
Transaction date
Purchase
Price
17.00
Quantity 175,000 +83.9%
Value US$2,975,000
Sofinnova Venture Partners VIII, L.P. Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 270,000 +15.3%
Value US$4,590,000
ORBIMED ADVISORS LLC Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 250,000 +10.6%
Value US$4,250,000
New Leaf Ventures II, L.P. Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 270,000 +161.2%
Value US$4,590,000
George Simeon Non-Executive Director Large shareholder
Transaction date
Purchase
Price
17.00
Quantity 270,000 +11.5%
Value US$4,590,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2020-09-22 2020-09-18 PlS Planned sale
Hardiman Roy C.

Chief Business Officer

Officer
70,440 +9.8%
307.03
US$1,683,530 		70,440 +9.8% 307.03 US$1,683,530
2020-08-20 2020-08-18 PlS Planned sale
CHAI CHRISTOPHER Y

Chief Financial Officer

Officer
52,104 -10.1%
11.76
US$1,063,725 		52,104 -10.1% 11.76 US$1,063,725
2020-08-20 2020-08-18 PlS Planned sale
Thomas Dolca

Chief Medical Officer

Officer
57,155 -16.2%
220.60
US$4,864,688 		57,155 -16.2% 220.60 US$4,864,688
2020-08-12 2020-08-10 PlS Planned sale
Goldstein David M

Chief Scientific Officer

Officer
100 -0.3%
93.34
US$9,334 		100 -0.3% 93.34 US$9,334
2020-08-12 2020-08-10 PlS Planned sale
Goldstein David M

Chief Scientific Officer

Officer
1,108 -3.4%
90.99
US$100,816 		1,108 -3.4% 90.99 US$100,816
2020-08-12 2020-08-10 PlS Planned sale
Goldstein David M

Chief Scientific Officer

Officer
700 -2.1%
89.68
US$62,773 		700 -2.1% 89.68 US$62,773
2020-08-12 2020-08-10 PlS Planned sale
Goldstein David M

Chief Scientific Officer

Officer
2,534 -7.0%
88.40
US$224,012 		2,534 -7.0% 88.40 US$224,012
2020-08-12 2020-08-10 PlS Planned sale
Goldstein David M

Chief Scientific Officer

Officer
700 -1.9%
86.92
US$60,844 		700 -1.9% 86.92 US$60,844
2020-08-12 2020-08-10 PlS Planned sale
Goldstein David M

Chief Scientific Officer

Officer
858 -2.3%
86.11
US$73,886 		858 -2.3% 86.11 US$73,886
2020-07-17 2020-07-15 PlS Planned sale
Thomas Dolca

Chief Medical Officer

Officer
15,000 -89.1%
80.07
US$1,201,070 		15,000 -89.1% 80.07 US$1,201,070
2020-07-02 2020-07-01 PlS Planned sale
0.8
Colowick Alan
Non-Executive Director
7,500 -100.0%
60.00
US$450,000 		7,500 -100.0% 60.00 US$450,000
2020-06-25 2020-06-23 PlS Planned sale
0.5
Babler Martin

President, CEO

Executive Director
2,502 -75.5%
62.38
US$156,078 		2,502 -75.5% 62.38 US$156,078
2020-06-25 2020-06-23 PlS Planned sale
0.5
Babler Martin

President, CEO

Executive Director
11,983 -78.3%
61.82
US$740,745 		11,983 -78.3% 61.82 US$740,745
2020-06-25 2020-06-23 PlS Planned sale
0.5
Babler Martin

President, CEO

Executive Director
515 -3.3%
60.32
US$31,066 		515 -3.3% 60.32 US$31,066
2020-06-17 2020-06-15 PlS Planned sale
3.5
Wolff Stefani

Chief Development Officer

Officer
100 -0.5%
61.37
US$6,137 		100 -0.5% 61.37 US$6,137
2020-06-17 2020-06-15 PlS Planned sale
3.5
Wolff Stefani

Chief Development Officer

Officer
5,004 -20.7%
60.81
US$304,291 		5,004 -20.7% 60.81 US$304,291
2020-06-17 2020-06-15 PlS Planned sale
3.5
Wolff Stefani

Chief Development Officer

Officer
400 -1.6%
59.89
US$23,957 		400 -1.6% 59.89 US$23,957
2020-06-15 2020-06-12 PlS Planned sale
Hardiman Roy C.

Chief Business Officer

Officer
863 -0.7%
62.13
US$53,617 		863 -0.7% 62.13 US$53,617
2020-06-15 2020-06-12 PlS Planned sale
Hardiman Roy C.

Chief Business Officer

Officer
2,542 -2.1%
61.62
US$156,630 		2,542 -2.1% 61.62 US$156,630
2020-06-15 2020-06-12 PlS Planned sale
Hardiman Roy C.

Chief Business Officer

Officer
1,595 -1.3%
59.90
US$95,541 		1,595 -1.3% 59.90 US$95,541
2020-05-21 2020-05-19 PlS Planned sale
CHAI CHRISTOPHER Y

Chief Financial Officer

Officer
7,500 -67.9%
65.10
US$488,268 		7,500 -67.9% 65.10 US$488,268
2020-05-08 2020-05-07 PlS Planned sale
Goldstein David M

Chief Scientific Officer

Officer
2,719 -8.1%
60.39
US$164,207 		2,719 -8.1% 60.39 US$164,207
2020-05-08 2020-05-07 PlS Planned sale
Goldstein David M

Chief Scientific Officer

Officer
3,281 -8.9%
59.96
US$196,734 		3,281 -8.9% 59.96 US$196,734
2020-05-05 2020-05-05 PlS Planned sale
0.8
Colowick Alan
Non-Executive Director
6,660 -100.0%
60.00
US$399,600 		6,660 -100.0% 60.00 US$399,600
2020-05-05 2020-05-01 PlS Planned sale
0.8
Colowick Alan
Non-Executive Director
840 -100.0%
60.07
US$50,457 		840 -100.0% 60.07 US$50,457
2020-03-18 2020-03-16 PlS Planned sale
3.5
Wolff Stefani

Chief Development Officer

Officer
3,750 -9.5%
46.36
US$173,838 		3,750 -9.5% 46.36 US$173,838
2020-03-18 2020-03-16 PlS Planned sale
3.5
Wolff Stefani

Chief Development Officer

Officer
1,754 -4.3%
45.72
US$80,192 		1,754 -4.3% 45.72 US$80,192
2020-03-17 2020-03-13 PlS Planned sale
Hardiman Roy C.

Chief Business Officer

Officer
100 -0.1%
51.04
US$5,104 		100 -0.1% 51.04 US$5,104
2020-03-17 2020-03-13 PlS Planned sale
Hardiman Roy C.

Chief Business Officer

Officer
1,181 -1.0%
49.46
US$58,408 		1,181 -1.0% 49.46 US$58,408
2020-03-17 2020-03-13 PlS Planned sale
Hardiman Roy C.

Chief Business Officer

Officer
3,719 -3.1%
48.21
US$179,304 		3,719 -3.1% 48.21 US$179,304
2020-03-05 2020-03-03 PlS Planned sale
0.5
Babler Martin

President, CEO

Executive Director
300 -0.8%
64.83
US$19,448 		300 -0.8% 64.83 US$19,448
2020-03-05 2020-03-03 PlS Planned sale
0.5
Babler Martin

President, CEO

Executive Director
5,432 -12.1%
64.10
US$348,180 		5,432 -12.1% 64.10 US$348,180
2020-03-05 2020-03-03 PlS Planned sale
0.5
Babler Martin

President, CEO

Executive Director
7,183 -13.8%
63.24
US$454,251 		7,183 -13.8% 63.24 US$454,251
2020-03-05 2020-03-03 PlS Planned sale
0.5
Babler Martin

President, CEO

Executive Director
2,085 -3.8%
62.45
US$130,203 		2,085 -3.8% 62.45 US$130,203
2020-02-20 2020-02-18 PlS Planned sale
CHAI CHRISTOPHER Y

Chief Financial Officer

Officer
76 -1.6%
68.52
US$5,208 		76 -1.6% 68.52 US$5,208
2020-02-20 2020-02-18 PlS Planned sale
CHAI CHRISTOPHER Y

Chief Financial Officer

Officer
2,240 -31.6%
68.13
US$152,612 		2,240 -31.6% 68.13 US$152,612
2020-02-20 2020-02-18 PlS Planned sale
CHAI CHRISTOPHER Y

Chief Financial Officer

Officer
605 -7.9%
67.08
US$40,582 		605 -7.9% 67.08 US$40,582
2020-02-20 2020-02-18 PlS Planned sale
CHAI CHRISTOPHER Y

Chief Financial Officer

Officer
1,350 -14.9%
65.94
US$89,021 		1,350 -14.9% 65.94 US$89,021
2020-02-20 2020-02-18 PlS Planned sale
CHAI CHRISTOPHER Y

Chief Financial Officer

Officer
545 -5.7%
64.91
US$35,375 		545 -5.7% 64.91 US$35,375
2020-02-20 2020-02-18 PlS Planned sale
CHAI CHRISTOPHER Y

Chief Financial Officer

Officer
2,684 -21.9%
63.86
US$171,389 		2,684 -21.9% 63.86 US$171,389
2020-02-12 2020-02-10 PlS Planned sale
Goldstein David

Chief Scientific Officer

Officer
5,200 -14.4%
71.11
US$369,779 		5,200 -14.4% 71.11 US$369,779
2020-02-12 2020-02-10 PlS Planned sale
Goldstein David

Chief Scientific Officer

Officer
800 -2.2%
69.53
US$55,622 		800 -2.2% 69.53 US$55,622
2019-12-20 2019-12-19 S Sale Thomas Dolca

Chief Medical Officer

Officer
495 -50.1%
60.00
US$29,700 		495 -50.1% 60.00 US$29,700
2019-12-19 2019-12-18 PlS Planned sale Babler Martin

President, CEO

Executive Director
1,295 -7.6%
54.28
US$70,292 		1,295 -7.6% 54.28 US$70,292
2019-12-19 2019-12-18 PlS Planned sale Babler Martin

President, CEO

Executive Director
2,205 -11.5%
53.69
US$118,392 		2,205 -11.5% 53.69 US$118,392
2019-12-19 2019-12-18 PlS Planned sale Babler Martin

President, CEO

Executive Director
1,000 -5.0%
52.77
US$52,775 		1,000 -5.0% 52.77 US$52,775
2019-12-19 2019-12-17 PlS Planned sale Babler Martin

President, CEO

Executive Director
1,014 -1.8%
54.36
US$55,116 		1,014 -1.8% 54.36 US$55,116
2019-12-19 2019-12-17 PlS Planned sale Babler Martin

President, CEO

Executive Director
6,661 -10.8%
53.94
US$359,314 		6,661 -10.8% 53.94 US$359,314
2019-12-19 2019-12-17 PlS Planned sale Babler Martin

President, CEO

Executive Director
11,485 -15.7%
52.86
US$607,064 		11,485 -15.7% 52.86 US$607,064
2019-12-19 2019-12-17 PlS Planned sale Babler Martin

President, CEO

Executive Director
5,840 -7.4%
51.80
US$302,502 		5,840 -7.4% 51.80 US$302,502
2019-12-18 2019-12-16 PlS Planned sale Wolff Stefani

Chief Development Officer

Officer
1,300 -3.5%
49.87
US$64,825 		1,300 -3.5% 49.87 US$64,825
2019-12-18 2019-12-16 PlS Planned sale Wolff Stefani

Chief Development Officer

Officer
4,205 -10.2%
49.29
US$207,266 		4,205 -10.2% 49.29 US$207,266
2019-12-13 2019-12-13 PlS Planned sale Hardiman Roy C.

Chief Business Officer

Officer
1,619 -1.3%
49.83
US$80,682 		1,619 -1.3% 49.83 US$80,682
2019-12-13 2019-12-13 PlS Planned sale Hardiman Roy C.

Chief Business Officer

Officer
3,381 -2.7%
49.20
US$166,352 		3,381 -2.7% 49.20 US$166,352
2019-11-22 2019-11-20 B Purchase Becker Daniel J. Non-Executive Director
55,000 +9.0%
29.94
US$1,646,700 		55,000 +9.0% 29.94 US$1,646,700
2019-11-08 2019-11-07 PlS Planned sale Goldstein David

Chief Scientific Officer

Officer
10,000 -25.1%
32.39
US$323,914 		10,000 -25.1% 32.39 US$323,914
2019-10-30 2019-10-29 B Purchase
3.2
Becker Daniel J.
9,196 +1.5%
33.98
US$312,477 		9,196 +1.5% 33.98 US$312,477
2019-10-30 2019-10-28 B Purchase
3.2
Becker Daniel J.
68,404 +12.8%
33.41
US$2,285,549 		68,404 +12.8% 33.41 US$2,285,549
2019-10-22 2019-10-18 B Purchase
2.3
GLAXOSMITHKLINE PLC
357,142 +13.6%
28.00
US$9,999,976 		357,142 +13.6% 28.00 US$9,999,976
2019-10-22 2019-10-18 B Purchase
3.2
Becker Daniel J.
535,000 +inf%
28.00
US$14,980,000 		535,000 +inf% 28.00 US$14,980,000
2019-10-22 2019-10-18 B Purchase
3.1
George Simeon
357,142 +13.6%
28.00
US$9,999,976 		357,142 +13.6% 28.00 US$9,999,976
2019-08-15 2019-08-13 S Sale New Leaf Ventures II, L.P. Large shareholder
49,991 -11.4%
35.00
US$1,749,685 		49,991 -11.4% 35.00 US$1,749,685
2019-08-15 2019-08-13 S Sale New Leaf Ventures II, L.P. Large shareholder
250,009 -11.4%
35.00
US$8,750,315 		250,009 -11.4% 35.00 US$8,750,315
2019-05-22 2019-05-21 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
1,000,000 -38.4%
30.25
US$30,250,000 		1,000,000 -38.4% 30.25 US$30,250,000
2018-09-20 2018-09-18 B Purchase GLAXOSMITHKLINE PLC Large shareholder
270,000 +11.5%
17.00
US$4,590,000 		270,000 +11.5% 17.00 US$4,590,000
2018-09-20 2018-09-18 B Purchase Becker Daniel J. Non-Executive Director Large shareholder
270,000 +161.2%
17.00
US$4,590,000 		270,000 +161.2% 17.00 US$4,590,000
2018-09-20 2018-09-18 B Purchase AKKARAJU SRINIVAS Non-Executive Director
175,000 +83.9%
17.00
US$2,975,000 		175,000 +83.9% 17.00 US$2,975,000
2018-09-20 2018-09-18 B Purchase Sofinnova Venture Partners VIII, L.P. Large shareholder
270,000 +15.3%
17.00
US$4,590,000 		270,000 +15.3% 17.00 US$4,590,000
2018-09-20 2018-09-18 B Purchase ORBIMED ADVISORS LLC Large shareholder
250,000 +10.6%
17.00
US$4,250,000 		250,000 +10.6% 17.00 US$4,250,000
2018-09-20 2018-09-18 B Purchase New Leaf Ventures II, L.P. Large shareholder
270,000 +161.2%
17.00
US$4,590,000 		270,000 +161.2% 17.00 US$4,590,000
2018-09-20 2018-09-18 B Purchase George Simeon Non-Executive Director Large shareholder
270,000 +11.5%
17.00
US$4,590,000 		270,000 +11.5% 17.00 US$4,590,000
Explore more

More insider trading research around Principia Biopharma Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America